Respiratory Syncytial Virus Prevention: A New Era of Vaccines
- Calvin Yee Fen Lee; Salman Khan; Fnu Vishal; Sadaf Alam; Syeda Murtaza
Access Resources
About
This editorial discusses new vaccines for preventing respiratory syncytial virus (RSV) infections. RSV affects the lungs and can be serious, especially in young children and older adults. The FDA approved two vaccines: Nirsevimab for infants born at 35 weeks or more, and RSVPreF3 OA for adults over 60. Both target the virus's pre-F protein to stop it from attaching to cells. Studies show they reduce hospital visits and severe cases of RSV with mild side effects like headaches or tiredness. Single doses make them easy to use, potentially saving many lives worldwide.
Tags
More like this
The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.